Improving Access and Care for All Patients With Atopic Dermatitis

EP: 1.Understanding Atopic Dermatitis as an Immune-Mediated Disease

EP: 2.Bridging the Gaps: Health Care Professional Knowledge Gaps in AD Pathophysiology

EP: 3.Beyond the Itch: The Full Spectrum of AD Symptoms and Their Impact on Patients

EP: 4.Recognizing AD Across All Skin Tones

EP: 5.Diagnostic Challenges and Patient Education Across Skin Tones

EP: 6.Biologic Therapy Decision-Making and Monitoring in AD

EP: 7.Access, Adaptation, and Cost-Effectiveness in AD Treatment

EP: 8.Empowering Health Care Professionals: Training and Resources for Diverse AD Care

EP: 9.Atopic Dermatitis Clinical Trial Representation: Addressing Historical Gaps

EP: 10.Modern Clinical Trials: ADmirable and DISCOVER Data Insights for a Diverse Patient Population

EP: 11.From Research to Practice: Translating AD Clinical Trial Results and Overcoming Barriers

Now Viewing

EP: 12.Improving Access and Care for All Patients With Atopic Dermatitis

Content above is prompted by the following:

Health care systems are implementing diverse initiatives to improve access to specialist care and advanced therapies for underserved patients with atopic dermatitis. Andrew Alexis, MD, MPH, highlights the importance of integrated specialty pharmacy services within health systems, which provide comprehensive support for prior authorizations, patient assistance programs, and ongoing medication management. The availability of clinical trial data representing diverse populations helps overcome patient mistrust by demonstrating treatment effectiveness in populations that mirror their demographics, creating stronger therapeutic relationships and improved adherence.

Geographic and transportation barriers are being addressed through innovative delivery models, including dedicated clinics in underserved areas and expanded telehealth services. Andrew M. Mastro, MS, PA-C, describes opening clinics specifically for uninsured, self-pay, and Medicaid patients, while also conducting clinical trials that provide access to advanced therapies for patients who might otherwise lack coverage. April W. Armstrong’s, MD, MPH, research demonstrates equivalent clinical outcomes between in-person and telehealth care for atopic dermatitis, supporting expanded virtual care options that eliminate transportation barriers.

Financial barriers are being addressed through creative funding mechanisms, including 340B program utilization and internal patient financial assistance programs. Mark Makhinson, PharmD, describes Mount Sinai’s approach of funding access to expensive biologics for underinsured or uninsured patients through their "we find a way" philosophy. These comprehensive approaches recognize that improving patient access requires addressing multiple barriers simultaneously—from initial diagnosis and specialist referral through ongoing treatment support and financial assistance. Success requires coordinated efforts across multiple stakeholders, including health care providers, health systems, payers, and pharmaceutical companies working together to ensure equitable access to advanced atopic dermatitis treatments.